Recently, HDAC3 inhibitors have been proved to suppress degeneration and improve behavioral performance in multiple neurodegenerative conditions, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s ataxia, spinal cord injury, and ischemic stroke [140–144]. This evidence concerns the gene HDAC3 and Friedreich ataxia.